EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Characterization of the effect of naltrexone/bupropion on body composition

Vanessa Tardio iD, Peter Yin, Fernando Camacho, Maxime Barakat, Michael A Tsoukas iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16235 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Vanessa Tardio und 4 weiteren Autor:innen. Beteiligte Einrichtung: McGill University Health Centre, Division of Endocrinology, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Naltrexone, Body Composition, Weight Loss, Bupropion. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Orexigen Therapeutics, Bausch Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Oral treatment extended‐release naltrexone/bupropion (NB) leads to significant weight loss, but its effect on body composition remains unclear. We investigated changes in body composition with dual‐energy x‐ray absorptiometry after treatment with NB or placebo in a subgroup of participants from a randomized control phase 3 study (COR‐I). Materials and Methods Observed changes from baseline to week 52 were estimated for total, lean, and fat mass. Changes in body composition were evaluated using linear regression and adjusted for baseline covariates.

Results

The analysis included 82 participants (placebo, n = 26; NB, n = 56) with comparable baseline characteristics (age, BMI, sex). The NB group experienced a significant −7.8% change of total mass (−12.9% change in fat mass and −4.1% in lean mass), compared with a −2.8% change of total mass (−4.8% change in fat mass and −1.4% in lean mass) in the placebo group. The adjusted changes in lean‐to‐fat mass ratio of 0.069 in the NB group and −0.056 in the placebo group were significantly different ( p < 0.05).

Conclusions

NB‐induced weight loss is associated with significant reductions in total percent fat mass, increase in total percent lean mass, and change in lean‐to‐fat mass ratio, in comparison to placebo. Larger studies are needed to further elucidate the clinical significance of these changes and impact of a potentially healthier metabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaltrexoneBody CompositionWeight LossBupropionObesityAnti-Obesity AgentsHumansMaleFemaleAdultMiddle AgedAbsorptiometry, PhotonDrug CombinationsDouble-Blind MethodBody Mass IndexNarcotic Antagonists

Stichwörter der Autor:innen

body compositionnaltrexone/bupropionobesityoverweightweight loss

Substanzen

NaltrexoneBupropionDrug CombinationsAnti-Obesity AgentsNarcotic Antagonists

Autor:innen und Institutionen

  • McGill University Health Centre, Division of Endocrinology, Montreal, Quebec, Canada.
  • Medical Affairs, Bausch Health, Laval, Quebec, Canada.
  • DAMOS Inc., Toronto, Ontario, Canada.

ORCID-Profile: Vanessa Tardio, Michael A Tsoukas

Förderung

  • Orexigen Therapeutics
  • Bausch Health

Zitieren

APA

Tardio, V., Yin, P., Camacho, F., Barakat, M., & Tsoukas, M. A. (2025). Characterization of the effect of naltrexone/bupropion on body composition. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16235

Vancouver

Tardio V, Yin P, Camacho F, Barakat M, Tsoukas MA. Characterization of the effect of naltrexone/bupropion on body composition. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16235

BibTeX
@article{Tardio2025,
  author = {Tardio, Vanessa and Yin, Peter and Camacho, Fernando and Barakat, Maxime and Tsoukas, Michael A},
  title = {Characterization of the effect of naltrexone/bupropion on body composition},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16235}
}
Kostenlos starten →